Catalog No.: PC-70177Not For Human Use, Lab Use Only.
VMY-1-103 is a dansylated analog of purvalanol B, and a CDK inhibitor that inhibits cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B.
VMY-1-103 is a dansylated analog of purvalanol B, and a CDK inhibitor that inhibits cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B.
VMY-1-103 increases the sub G(1) fraction of apoptotic cells, induces PARP and caspase-3 cleavage and increases the levels of the death receptors DR4 and DR5, Bax and Bad.
